Takip et
Nicholas James
Nicholas James
Professor of Prostate and Bladder Cancer Research, Institute of Cancer Research
icr.ac.uk üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ...
New England Journal of Medicine 351 (15), 1502-1512, 2004
74492004
Alpha emitter radium-223 and survival in metastatic prostate cancer
C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, ...
New England Journal of Medicine 369 (3), 213-223, 2013
39172013
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group
Lancet (London, England) 397 (10285), 1637, 2021
2242*2021
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
22282016
Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
19152017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
12112018
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer
ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ...
New England Journal of Medicine 366 (16), 1477-1488, 2012
10762012
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
JCC Hu, RS Coffin, CJ Davis, NJ Graham, N Groves, PJ Guest, ...
Clinical cancer research 12 (22), 6737-6747, 2006
6872006
Confronting false discoveries in single-cell differential expression
JW Squair, M Gautier, C Kathe, MA Anderson, ND James, TH Hutson, ...
Nature communications 12 (1), 5692, 2021
6092021
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind …
O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ...
The Lancet Oncology 15 (7), 738-746, 2014
5802014
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019)
ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ...
European urology 67 (6), 1028-1038, 2015
5432015
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
5392018
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ...
Medrxiv, 2021.06. 15.21258542, 2021
534*2021
Required growth facilitators propel axon regeneration across complete spinal cord injury
MA Anderson, TM O’Shea, JE Burda, Y Ao, SL Barlatey, AM Bernstein, ...
Nature 561 (7723), 396-400, 2018
5052018
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of …
CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ...
The lancet oncology 17 (2), 243-256, 2016
5032016
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
4292019
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review
G Ploussard, S Daneshmand, JA Efstathiou, HW Herr, ND James, ...
European urology 66 (1), 120-137, 2014
4142014
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ...
European urology 77 (4), 508-547, 2020
3942020
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
3932015
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior …
CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, JM Ferrero, ...
Journal of clinical oncology 27 (32), 5431-5438, 2009
3922009
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20